|
|||||
|
|
An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer |
|
| Authors: | Roberto Pili Michael Carducci Peter Brown Herbert Hurwitz |
| Affiliation: | 1. Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA 2. Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA 3. Teva Branded Pharmaceutical Products R&D, Inc, Frazer, PA, USA 4. Duke Cancer Institute, Duke University, Durham, NC, USA |
| Abstract: | |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |